3Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [ J ]. N Engl J Med,2003,348(19) :1875 - 1883.
4Rosifiol L, Ofiol A, Teruel AI, et al. Superiority of bortezomib,tha- lidomide, and dexamethasone(VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study[J]. Blood,2012,120(8) :1589 - 1596.
5Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double an- tologous stem-cell transplantation in newly diagnosed multiple myelo- ma: a randomised phase 3 study [ J ]. Lancet, 2010,376 ( 9758 ) : 2075 - 2085.
6Mohty M, Harousseau JL. Treatment of autologous stem cell transplant- eligible multiple myeloma patients: ten questions and answers [ J ]. Haematologica, 2014,99 ( 3 ) :408 - 416.
7Maiolino A, Hungria VT, Garnica M, et al. Thalidomide plus dexa- methasone as a maintenance therapy .after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma[ J ]. Am J Hematol, 2012,87 (10) :948 - 952.